NYSE:RVTYLife Sciences
How Investors May Respond To Revvity (RVTY) Divesting Its China Immunodiagnostics Business
In early June 2026, Revvity announced plans to divest its immunodiagnostics business in China, which accounted for about 6% of revenue, after reporting first-quarter results that included 6% pro forma organic growth and a 24% adjusted operating margin across Life Sciences, Diagnostics, and SaaS software.
This move signals a refocus on higher-growth, higher-margin areas while shedding a business constrained by policy challenges and cash flow pressures in China.
Next, we’ll examine how the...